A Study to Evaluate Abbv-951 in Subjects with Parkinson's Disease (H-47966)

An Open-Label Extension of Study M15-741 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure to Continuous Subcutaneous Infusion of Abbv-951 in Subjects with Parkinson's Disease. 

The purpose of this study is to continue testing whether ABBV-951 is generally safe in subjects with Parkinson's disease after completion of the parent study, M15-741.  The study also continues to seek to find out how well ABBV-951 works to control Parkinson's disease symptoms. 

ABBV-951 is given as a 24-hour continuous subcutaneous (under the skin) infusion using an infusion pump.  Participants are trained on how to operate the pump.  

This is an open-label study, which means participants and the study doctor and study staff know that the participant is receiving the ABBV-951.

This study is closed for enrollment.